Loss of p53 tumor-suppressor function is the most common abnormality in human cancer,
which can result in enhanced presentation to immune cells of wild-type (wt)-sequence …

Approximately 50% of human malignancies carry p53 mutations, which makes it a potential
antigenic target for cancer immunotherapy. Adoptive transfer with p53-specific cytotoxic T …

Genetic alterations in p53 are common to a wide range of human tumors, including
squamous cell carcinomas of the head and neck. Given the need for novel adjuvant …

Immunotherapy, including immune checkpoint blockade and chimeric antigen receptor T
cells, is one of the most promising approaches to treat cancer. Vaccines have been effective …

Wild-type sequence (wt) p53 peptides are attractive candidates for broadly applicable
cancer vaccines. Six HLA-A2 or HLA-A24-restricted wt p53 peptides were evaluated for their …

Mutation in the p53 gene based on single amino acid substitutions is a frequent event in
human cancer. Accumulated mutant p53 protein is released to antigen presenting cells of …

Background The cellular regulatory protein p53 is overexpressed by almost 50% of all
malignancies making it an attractive target for a vaccine approach to cancer. A number of …

Squamous cell carcinomas of the head and neck (HNSCCs) are characterized by a high
frequency of mutations in the p53 gene often leading to p53 protein accumulation. Since …

Purpose: Wild-type sequence (wt) p53 peptides are attractive candidates for broadly
applicable cancer vaccines, currently considered primarily for patients whose tumors …

Immunotherapy targeting p53 missense mutations, which occur in nearly half of all human
tumors, is limited by several factors, including the constraints of antigen processing and …